

 Early Warning System

IFC-606205

Anhui Biochem Pharmaceutical (Africa)



Quick Facts

Financial Institutions	International Finance Corporation (IFC)
Status	Active
Bank Risk Rating	U
Borrower	Anhui Biochem United Pharmaceutical Co.
Sectors	Education and Health, Finance
Investment Type(s)	Advisory Services
Project Cost (USD)	\$ 0.15 million



Project Description

This Upstream Project entails an opportunity for IFC to support Anhui Biochem United Pharmaceutical Co., Ltd. (“Anhui Biochem”) to identify and develop opportunities for the local production for HIV/AIDS and Hepatitis B drugs in selected African countries through the creation of local manufacturing partnerships. Anhui Biochem is one of China's leading biotech companies engaged in the development, manufacturing and supply of antiretroviral drugs, currently exporting its products to 33 countries. Increasing local pharmaceutical production will potentially ease the current strain on African government budgets and foreign exchange demands arising from a high reliance on imported products critical for the treatment of killer diseases such as HIV/AIDS and Hepatitis B. In addition, on-continent production will reduce the vulnerability of African populations to the type of supply-chain disruptions encountered as a result of the COVID-19 pandemic.

The Project requires Upstream support to identify the markets with: (i) the strongest manufacturing capabilities, (ii) a well-suited enabling environment, (iii) appropriate potential local partners, (iv) an evaluation of the technological and economic feasibility of each opportunity backed by well-structured economic and financial analyses, and (v) a compilation of the project roadmap to investment. IFC intends to provide advisory services to facilitate partner engagements, as well as co-funding and relevant internal expertise to manage external consulting engagements and studies required to reach investment readiness within the next three years.



People Affected By This Project

The project seeks to build and strengthen local pharmaceutical and medical manufacturing capabilities. In turn, the project will result in (i) increasing availability of critical pharmaceutical products in Africa and (ii) diversifying the pharmaceutical value chain and increasing local manufacturing capacities for critical pharmaceutical products. Overall, this increases resilience of the country and the region, especially during times of supply chain disruptions as demonstrated by COVID-19.



Investment Description

- International Finance Corporation (IFC)



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Anhui Biochem United Pharmaceutical Co.	Client	-



Contact Information

"No contacts available at the time of disclosure."

ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>